The idea of a combination treatment is not new in LAM, as in 2015, Alayev and colleagues reported promising results from combining Rapamycin with resveratrol, an autophagy inhibitor, in a Tsc2-null xenograft tumor model. Here, TSC2 is linked to neoplasm.